ESMO Breast Cancer 2026 was not defined by one single headline. It was a congress about treatment refinement: using better drugs earlier, reducing chemotherapy when safe, improving quality of life, understanding resistance, and asking whether biomarkers can help clinicians make more precise decisions across every breast cancer subtype.
The strongest theme was clear: breast oncology is moving beyond “more treatment” as the default answer. The field is increasingly asking how to deliver the right intensity of treatment, for the right patient, at the right time, while preserving long-term function and quality of life. ESMO Daily Reporter framed several of the major meeting themes around chemotherapy-free strategies, ADC sequencing, ctDNA uncertainty, SERD development, invasive lobular cancer biology, and liquid biopsy across the breast cancer continuum.
TROPION-Breast02: Dato-DXd Moves First-Line TNBC Beyond Chemotherapy Alone
One of the most important metastatic breast cancer milestones came from TROPION-Breast02, evaluating first-line datopotamab deruxtecan (Dato-DXd) versus investigator’s choice chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer for whom immunotherapy was not an option.
The primary phase III data had already shown a major efficacy signal: median progression-free survival was 10.8 months with Dato-DXd versus 5.6 months with chemotherapy, while median overall survival was 23.7 months versus 18.7 months, respectively. Treatment-related grade 3 or higher adverse events occurred in 33% with Dato-DXd and 29% with chemotherapy, and treatment discontinuation due to treatment-related adverse events was 4% versus 7%.
At ESMO Breast Cancer 2026, the patient-reported outcome analysis added the missing patient-centered layer. Dato-DXd delayed deterioration in global health status, physical functioning, and arm symptoms compared with chemotherapy. This matters because in metastatic TNBC, better survival is not enough if treatment rapidly worsens daily function. TROPION-Breast02 suggests that Dato-DXd may improve outcomes while also preserving patient experience in a population with limited first-line options.
Read About TROPION-Breast02 Trial on OncoDaily
evERA Breast Cancer: Giredestrant Plus Everolimus Brings Efficacy With Manageable Tolerability
The phase III evERA Breast Cancer trial was another key post-CDK4/6 story. The study evaluated giredestrant plus everolimus versus standard endocrine therapy plus everolimus in ER-positive, HER2-negative advanced breast cancer previously treated with a CDK4/6 inhibitor.
The primary analysis had already shown that giredestrant plus everolimus improved progression-free survival over standard endocrine therapy plus everolimus. The safety and patient-reported outcome presentation focused on whether that benefit came at the cost of treatment burden.
The answer was reassuring. Quality of life was maintained, time to deterioration in function numerically favored giredestrant plus everolimus, and steroid mouthwash prophylaxis reduced clinically significant everolimus-associated stomatitis. In the giredestrant arm, grade 2 stomatitis was lower with prophylaxis than without prophylaxis, and grade 3 stomatitis was also numerically reduced. The key practical message is simple: this regimen needs proactive toxicity prevention, but with supportive care, it appears clinically manageable.
This was also part of a broader SERD milestone at the meeting. ESMO Daily Reporter highlighted that giredestrant showed robust anti-proliferative activity in young patients with ER-positive/HER2-negative early breast cancer, supporting continued development of SERD-based endocrine strategies.
Read About evERA BC Trial on OncoDaily
CAPItello-291: Final OS Was Negative, but Disease Control Still Matters
The final overall survival analysis from CAPItello-291 was one of the most nuanced presentations of the congress. Capivasertib plus fulvestrant did not significantly improve overall survival compared with placebo plus fulvestrant in either the PIK3CA/AKT1/PTEN-altered population or the overall population.
That negative OS result is important and should not be softened. In the altered population, median OS was 28.5 months with capivasertib plus fulvestrant versus 30.4 months with placebo plus fulvestrant, with a hazard ratio of 0.83. In the overall population, the hazard ratio was 1.00.
However, CAPItello-291 still showed meaningful benefits in later disease-control endpoints. PFS2 and time to first subsequent chemotherapy or death favored capivasertib plus fulvestrant in both the altered and overall populations. This distinction matters because modern HR-positive metastatic breast cancer survival is increasingly affected by post-progression therapies. The right interpretation is not “OS-positive.” It is: capivasertib plus fulvestrant improves disease control and delays chemotherapy, even without a final OS advantage.
Read About CAPItello-291 Trial on OncoDaily
PHERGain-2 and the Chemotherapy-Free HER2 Future
HER2-positive early breast cancer had one of the strongest treatment-optimization narratives at ESMO Breast Cancer 2026. The question was not only whether patients can be cured, but whether some can be cured with less chemotherapy.
The PHERGain-2 study was highlighted as a pCR-guided chemotherapy-free strategy using trastuzumab and pertuzumab, with T-DM1 integrated according to response. ESMO Daily Reporter described PHERGain-2 as a study where a pathological complete response-guided approach enabled treatment optimization in a selected HER2-positive population while preserving quality of life.
This fits into a broader movement in HER2-positive disease: imaging-guided response assessment, pCR-adapted escalation, and chemotherapy omission for selected responders. The field is not yet at the point where chemotherapy-free HER2 therapy becomes universal standard practice. But ESMO Breast 2026 made clear that HER2-positive early breast cancer is one of the most advanced spaces for rational de-escalation.
Read About PHERGain-2 Trial on OncoDaily
PHERGain 5-Year Follow-Up: De-Escalation Needs Durable Proof
The 5-year invasive disease-free survival follow-up from PHERGain was another important milestone because de-escalation cannot be judged only by short-term response. A high pCR rate is encouraging, but long-term iDFS determines whether treatment reduction is truly safe.
The PHERGain long-term update reinforced the importance of following chemotherapy-free and response-adapted approaches beyond the neoadjuvant window. The key message is that de-escalation must prove durability, not just early activity.
TRAIN-4 and ctDNA-Guided HER2 De-Escalation
The TRAIN-4 trial added another layer to HER2-positive early breast cancer: combining chemotherapy-free HER2-targeted therapy with ctDNA monitoring. The regimen evaluated trastuzumab and pertuzumab plus tucatinib, using ctDNA as part of a modern response-assessment strategy.
This reflects a major direction in early breast cancer research. Traditional endpoints such as pCR remain essential, but molecular response may eventually help refine treatment intensity. However, ctDNA is not yet ready to replace clinical judgment in early disease. ESMO Daily Reporter specifically noted that ctDNA surveillance in early breast cancer remains uncertain, with data supporting feasibility but not yet proving clinical utility.
Pyrotinib Plus Pertuzumab: Another Signal for HER2-Targeted Chemo-Free Strategies
The pyrotinib plus pertuzumab neoadjuvant study with ctDNA monitoring continued the same theme: HER2-positive breast cancer is becoming a testing ground for chemotherapy-free, biomarker-guided approaches. The significance of this presentation is less about immediately changing practice and more about expanding the evidence base for dual HER2 blockade, HER2 TKIs, and molecular monitoring in early-stage disease.
Together with PHERGain-2 and TRAIN-4, this work suggests that the next generation of HER2-positive early breast cancer trials will increasingly ask whether response-guided therapy can preserve outcomes while reducing chemotherapy exposure.
HER2CLIMB-02: Tucatinib Plus T-DM1 and the Sequencing Question
In HER2-positive metastatic breast cancer, HER2CLIMB-02 continued the sequencing conversation. Tucatinib plus T-DM1 has been an important regimen because tucatinib has already established relevance in HER2-positive disease, especially where CNS activity matters.
The updated overall survival data are clinically important because the metastatic HER2-positive field is crowded with active therapies: trastuzumab deruxtecan, tucatinib-based combinations, T-DM1-based strategies, and post-T-DXd options. The key question is no longer whether HER2-targeted therapy works. It is how to sequence HER2 ADCs, TKIs, and antibody combinations in a way that preserves benefit across multiple lines.
Read About HER2CLIMB-02 Trial on OncoDaily
SATEEN: Sacituzumab Govitecan Plus Trastuzumab After T-DXd
The SATEEN trial addressed one of the most practical questions in HER2-positive metastatic breast cancer: what comes after trastuzumab deruxtecan?
Sacituzumab govitecan plus trastuzumab after prior T-DXd progression is important because it tests whether TROP2-directed ADC therapy can remain active in a HER2-positive population already exposed to a topoisomerase I ADC payload. This is exactly where ADC sequencing becomes difficult. If two ADCs share similar payload biology, simple target switching may not always overcome resistance.
That concern was also reflected in the ESMO Daily Reporter theme on ADC sequencing, which noted that the first prospective phase II trials evaluating a TOP1 ADC after prior TOP1 ADC therapy support the emergence of cross-resistance.
Read about SATEEN Trial on OncoDaily
HER3-DXd and HERTHENA-BC: The Pan-Breast ADC Expansion
HER3-directed ADC development also remained important. The HERTHENA-BC dose-expansion data for patritumab deruxtecan (HER3-DXd) across HR-positive/HER2-negative, HER2-positive, and triple-negative breast cancer reflects the broader ADC expansion beyond HER2 and TROP2.
This matters because breast cancer ADC development is moving from subtype-specific use toward target biology layered across subtypes. HER3, TROP2, HER2-low, HER2-ultralow, and other ADC targets are increasingly creating overlapping treatment possibilities. The challenge will be identifying which target should be used first, which payload remains active after prior ADC exposure, and which biomarkers can predict resistance.
DESTINY-Breast11 and Residual Disease Strategy After T-DXd
The neoadjuvant HER2-positive space also included interest around DESTINY-Breast11, evaluating T-DXd-based strategies and residual cancer burden approaches. This is part of a larger movement to bring ADCs earlier, potentially changing how clinicians think about neoadjuvant therapy, residual disease, and post-neoadjuvant escalation.
If ADCs continue moving into curative-intent settings, the field will need to answer different questions than in metastatic disease: not only response rate, but cardiac safety, ILD monitoring, fertility implications, long-term survivorship, and whether high early response can justify less chemotherapy.
UK Genetic Testing Programme: BRCA Testing as a Population-Level Milestone
The UK national genetic testing programme for germline BRCA1/2 in historic breast and ovarian cancer patients represented a different type of milestone: not a drug result, but a health-system intervention.
This matters because precision oncology depends on identifying eligible patients. Germline BRCA testing has implications not only for PARP inhibitor access but also for risk-reducing surgery, cascade testing, family counseling, and prevention. Large-scale testing programmes may become as important as drug development if they improve access to genomic information for patients who were diagnosed before modern testing became routine.
Invasive Lobular Breast Cancer Is Finally Being Treated as Biologically Distinct
Another major theme was the evolving management of invasive lobular breast cancer. ESMO Daily Reporter highlighted that advances in molecular profiling and understanding of lobular biology are reinforcing the concept that invasive lobular cancer is distinct from other ER-positive breast cancers.
This is important because lobular cancer has historically been treated as if it were simply another form of luminal breast cancer. Increasing evidence suggests that its metastatic pattern, endocrine sensitivity, late relapse behavior, imaging challenges, and molecular biology require more specific research. ESMO Breast 2026 gave this topic the attention it deserves.
Liquid Biopsy and ctDNA: Powerful, but Not Yet Settled
Liquid biopsy was another major pillar of the congress. Daniel F. Hayes, the 2026 ESMO Breast Cancer Awardee, was featured discussing the potential of liquid biopsy across the breast cancer spectrum.
The important nuance is that liquid biopsy is promising but not fully settled. ctDNA may help identify minimal residual disease, detect molecular relapse, guide escalation, or monitor treatment response. But the clinical utility of acting on ctDNA positivity, especially in early breast cancer surveillance, remains uncertain. The meeting reinforced the need for prospective trials proving that ctDNA-guided intervention improves outcomes rather than simply detecting relapse earlier.
The Bigger Message From ESMO Breast Cancer 2026
The congress showed a field moving in several directions at once. In metastatic TNBC, Dato-DXd is challenging chemotherapy in patients who cannot receive immunotherapy. In HR-positive disease, oral SERDs, AKT inhibition, and everolimus combinations are refining the post-CDK4/6 setting. In HER2-positive disease, chemotherapy-free strategies, pCR-guided treatment, tucatinib combinations, ADC sequencing, and ctDNA monitoring are reshaping both early and metastatic care.
The most important shift is conceptual. Breast oncology is no longer defined only by adding new therapies. It is increasingly defined by optimizing treatment intensity, understanding resistance, preserving quality of life, and making biomarker-driven decisions more practical in real-world care.
Clinical Takeaway
ESMO Breast Cancer 2026 was a congress about maturity in breast oncology. The field is learning that a better treatment is not only one that improves PFS or OS. It is one that patients can stay on, one that preserves function, one that delays chemotherapy, one that can be sequenced rationally, and one that fits the biology of the individual tumor.
The milestones to remember are TROPION-Breast02 in first-line metastatic TNBC, evERA and CAPItello-291 in the post-CDK4/6 HR-positive space, PHERGain-2 and related HER2 trials in chemotherapy-free early disease, HER2CLIMB-02 and SATEEN in metastatic HER2 sequencing, HER3-DXd and ADC cross-resistance as the next ADC frontier, and liquid biopsy as a promising but still unresolved tool.
This was not just a meeting of new data. It was a meeting about how breast cancer treatment is becoming more precise, more patient-centered, and more careful about what “benefit” really means.